Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Exelixis is conducting a Phase 1 clinical study titled ‘An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors.’ The study aims to assess the safety and preliminary efficacy of XL309, both alone and in combination with olaparib, in treating advanced solid tumors. This research is significant as it explores potential new treatment options for difficult-to-treat cancers.
The study is testing XL309, a drug administered orally once daily, and olaparib, which is taken twice daily. XL309 is being evaluated for its safety and effectiveness as a standalone treatment and in combination with olaparib, a known cancer therapy.
This interventional study is non-randomized and follows a sequential intervention model without masking, focusing primarily on treatment. The study is designed to determine the optimal dosing and assess the drug’s impact on tumor growth.
The study began on April 3, 2024, with an estimated completion date yet to be announced. The latest update was submitted on July 16, 2025, indicating ongoing recruitment and progress.
For investors, this study could influence Exelixis’s stock performance, as successful results might enhance the company’s market position in oncology. The development of XL309 could also impact competitors in the cancer treatment market, potentially shifting investor sentiment positively towards Exelixis.
The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.